Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Drugs (Pharmaceuticals) Suits and Litigation (Civil) Thalidomide (Drug) Celgene Corporation Whistle-Blowers Cancer Food and Drug Administration Source Type: news